Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN87293301
ISRCTN87293301
Completed
Not Applicable

Clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII in previously treated patients with severe haemophilia A

Octapharma AG (Switzerland)0 sites20 target enrollmentFebruary 3, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSevere haemophilia AHaematological DisordersHereditary factor VIII deficiency

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Severe haemophilia A
Sponsor
Octapharma AG (Switzerland)
Enrollment
20
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 3, 2009
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Octapharma AG (Switzerland)

Eligibility Criteria

Inclusion Criteria

  • •1\. Must have severe haemophilia A (FVIII:C less than 1%; historical value as documented in subject records)
  • •2\. Aged greater than 18 and less than 65 years, male
  • •3\. Body weight 45 kg to 110 kg
  • •4\. Previously treated with FVIII concentrate, at least 150 exposure days (EDs)
  • •5\. Immunocompetent (CD4\+ count greater than 200/µL)
  • •6\. Negative for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) or respective viral load less than 200 particles/µL
  • •7\. Freely given written informed consent

Exclusion Criteria

  • •1\. Other coagulation disorder than haemophilia A
  • •2\. Present or past FVIII inhibitor activity (greater than 0\.6 BU)
  • •3\. Severe liver or kidney disease (alanine aminotransferase \[ALAT] and aspartate aminotransferase \[ASAT] levels greater than 5 times of upper limit of normal, creatinine greater than 120 µmol/L)
  • •4\. Receiving or scheduled to receive immuno\-modulating drugs (other than anti\-retroviral chemotherapy) such as alpha\-interferon, prednisone (equivalent to greater than 10 mg/day), or similar drugs
  • •5\. Participation in another clinical study currently or during the past month

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-003681-34-PLOctapharma AG55
Active, not recruiting
Phase 1
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-003681-34-BGOctapharma AG55
Active, not recruiting
Phase 1
Study to Investigate the product Wilate in Patients with Severe Hemophilia ASevere hemophilia A (<1% FVIII:C)MedDRA version: 19.1Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-003681-34-HUOctapharma AG55
Active, not recruiting
Not Applicable
To determine the pharmacokinetics of human-cl rhFVIII in terms of the FVIII coagulant activity (FVIII:C) and to compare it with the licensed FVIII concentrate Kogenate/Helixate in previously treated subjects suffering from severe hemophilia A.
EUCTR2008-001563-11-BGOctapharma AG22
Active, not recruiting
Not Applicable
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of human-cl rhFVIII, a Newly Developed Human Cell-Line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A.Severe hemophilia A (FVIII:C <1%)
EUCTR2008-001563-11-DEOctapharma AG25